In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have designed a new method for developing immunotherapy drugs using engineered peptides to elicit a natural immune response inside the body.
New findings from Cleveland Clinic and Tufts University researchers show high blood levels of TMAO (trimethylamine N-oxide) predicts future risk of developing chronic kidney disease over time.